Literature DB >> 25257575

Hospital admissions after transrectal ultrasound-guided biopsy of the prostate in men diagnosed with prostate cancer: a database analysis in England.

Eleni Anastasiadis1, Jan van der Meulen, Mark Emberton.   

Abstract

OBJECTIVES: To investigate the complication rate within 30 days after transrectal ultrasound-guided biopsy of the prostate in England, and to examine associated risk factors.
METHODS: A population-based study was carried out using the English cancer registry linked to administrative hospital data. We included men aged 45 years and older diagnosed with prostate cancer between 2000 and 2008. A complication was considered to have occurred if men had been admitted to hospital as a result of urological causes (urinary tract infection/sepsis, hematuria and urinary retention) within 30 days of the transrectal ultrasound-guided biopsy of the prostate. Multivariable logistic regression was carried out to estimate odds ratios, reflecting the impact of risk factors on the complication rate.
RESULTS: Of the 198,361 included men, 69% were aged between 65 and 84 years. The 30-day complication rate was 3.7% (1.1% for urinary tract infection/sepsis, 1.4% for hematuria and 1.3% for urinary retention). The most important risk factors were age above 85 years (odds ratio 3.85, 95% confidence interval 3.18-4.67, compared with age below 55 years) and three or more comorbidities (odds ratio 3.50, 95% confidence interval 3.17-5.87, compared with no comorbidity). The overall complication rate increased over time (odds ratio 1.20, 95% confidence interval 1.08-1.34, 2008 compared with 2000), as did the complication rate as a result of urinary tract infection/sepsis (odds ratio 1.72, 95% confidence interval 1.41-2.10, 2008 compared with 2000).
CONCLUSIONS: There has been an increase in the complication rate after transrectal ultrasound-guided biopsy of the prostate in England between 2000 and 2008, predominantly as a result of infections. Age and comorbid conditions seem to represent the two most important risk factors for occurrence of post-biopsy complications.
© 2014 The Japanese Urological Association.

Entities:  

Keywords:  biopsy; diagnosis; infection; postoperative complications; prostatic neoplasms

Mesh:

Year:  2014        PMID: 25257575     DOI: 10.1111/iju.12634

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  11 in total

1.  Transrectal versus transperineal prostate biopsy under intravenous anaesthesia: a clinical, microbiological and cost analysis of 2048 cases over 11 years at a tertiary institution.

Authors:  Matthew J Roberts; Alastair Macdonald; Sachinka Ranasinghe; Harrison Bennett; Patrick E Teloken; Patrick Harris; David Paterson; Geoff Coughlin; Nigel Dunglison; Rachel Esler; Robert A Gardiner; Thomas Elliott; Louisa Gordon; John Yaxley
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-08-05       Impact factor: 5.554

2.  Rational antibiotic sustainability for transrectal prostate biopsy prophylaxis.

Authors:  Deepak K Pruthi; Michael A Liss
Journal:  Nat Rev Urol       Date:  2017-10-04       Impact factor: 14.432

3.  Dutasteride is associated with reduced risk of transrectal prostate biopsy-associated urinary tract infection and related hospitalizations.

Authors:  Daniel M Moreira; Gerald L Andriole; J Curtis Nickel; Claus G Roehrborn; Ramiro Castro-Santamaria; Stephen J Freedland
Journal:  World J Urol       Date:  2017-04-10       Impact factor: 4.226

4.  Cost-Effectiveness Analysis of Stockholm 3 Testing Compared to PSA as the Primary Blood Test in the Prostate Cancer Diagnostic Pathway: A Decision Tree Approach.

Authors:  Bettina Wulff Risør; Nasrin Tayyari Dehbarez; Jacob Fredsøe; Karina Dalsgaard Sørensen; Bodil Ginnerup Pedersen
Journal:  Appl Health Econ Health Policy       Date:  2022-08-08       Impact factor: 3.686

5.  Preliminary study on ultrasound-guided prostate biopsy specimen scores.

Authors:  Cheng Li; Weiwei Zhan; Minguang Zhang; Fangxiu Luo; Yan Wang; Bin Zheng
Journal:  Exp Ther Med       Date:  2017-07-18       Impact factor: 2.447

6.  Improving the safety and tolerability of local anaesthetic outpatient transperineal prostate biopsies: A pilot study of the CAMbridge PROstate Biopsy (CAMPROBE) method.

Authors:  D Thurtle; L Starling; K Leonard; T Stone; V J Gnanapragasam
Journal:  J Clin Urol       Date:  2018-03-05

7.  A Nomogram Based on a TRUS Five-Grade Scoring System for the Prediction of Prostate Cancer and High Grade Prostate Cancer at Initial TRUS-Guided Biopsy.

Authors:  Shao Wei Xie; Yan Qing Wang; Bai Jun Dong; Jian Guo Xia; Hong Li Li; Shi Jun Zhang; Feng Hua Li; Wei Xue
Journal:  J Cancer       Date:  2018-10-22       Impact factor: 4.207

8.  Multicentre clinical evaluation of the safety and performance of a simple transperineal access system for prostate biopsies for suspected prostate cancer: The CAMbridge PROstate Biopsy DevicE (CamPROBE) study.

Authors:  Vincent J Gnanapragasam; Kelly Leonard; Michal Sut; Cristian Ilie; Jonathan Ord; Jacques Roux; Maria Consuelo Hart Prieto; Anne Warren; Priya Tamer
Journal:  J Clin Urol       Date:  2020-06-12

Review 9.  Transperineal vs. transrectal biopsy in MRI targeting.

Authors:  Jeremy Grummet; Lana Pepdjonovic; Sean Huang; Elliot Anderson; Boris Hadaschik
Journal:  Transl Androl Urol       Date:  2017-06

10.  Genes involved in prostate cancer progression determine MRI visibility.

Authors:  Ping Li; Sungyong You; Christopher Nguyen; Yanping Wang; Jayoung Kim; Deepika Sirohi; Asha Ziembiec; Daniel Luthringer; Shih-Chieh Lin; Timothy Daskivich; Jonathan Wu; Michael R Freeman; Rola Saouaf; Debiao Li; Hyung L Kim
Journal:  Theranostics       Date:  2018-02-12       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.